MapLight Therapeutics

News

MapLight Therapeutics has made its debut on the Nasdaq, raising $251m for a lead drug that could be a rival to BMS' new schizophrenia drug Cobenfy.

News

Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.